Copper oxodotreotide
As of the edition of 20 October 2026, Copper oxodotreotide is a protein: marketed, first approved in 2020 (US); acts on SSTR2; US protection ends in 2027.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Protein
- Brand name
- Detectnet
- First approved
- 3 September 2020 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Curium
- Registered trials
- 5, 0 stopped early
- Disease areas
- Cancer; Skin and connective tissue
US protection
US protection ends in 2027.
The last listed US exclusivity ends in 2027. The application that gives this date is held by Curium.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Copper oxodotreotide.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SSTR2 | Somatostatin receptor type 2 | P30874 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 0 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 5 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Radiomedix | Originator and Lead sponsor of trials | 2018 to now |
| Curium | Acquired holder | 2025 to now |